Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $65.4 million.

  • Viking Therapeutics' Net Cash Flow rose 37725.98% to $65.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $139.1 million, marking a year-over-year increase of 58495.05%. This contributed to the annual value of $139.1 million for FY2025, which is 58495.05% up from last year.
  • Per Viking Therapeutics' latest filing, its Net Cash Flow stood at $65.4 million for Q4 2025, which was up 37725.98% from $66.5 million recorded in Q3 2025.
  • Viking Therapeutics' 5-year Net Cash Flow high stood at $140.1 million for Q1 2024, and its period low was -$151.7 million during Q2 2024.
  • Moreover, its 5-year median value for Net Cash Flow was $5.2 million (2022), whereas its average is $6.9 million.
  • As far as peak fluctuations go, Viking Therapeutics' Net Cash Flow surged by 119584.6% in 2023, and later crashed by 39645.62% in 2024.
  • Over the past 5 years, Viking Therapeutics' Net Cash Flow (Quarter) stood at $15.1 million in 2021, then crashed by 53.11% to $7.1 million in 2022, then skyrocketed by 158.1% to $18.3 million in 2023, then tumbled by 229.08% to -$23.6 million in 2024, then soared by 377.26% to $65.4 million in 2025.
  • Its Net Cash Flow stands at $65.4 million for Q4 2025, versus $66.5 million for Q3 2025 and -$4.0 million for Q2 2025.